Hartford Healthcare | Cancer Clinical Research Office
Status
Conditions
Treatments
About
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).
Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Individuals must meet all the following:
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study:
Primary purpose
Allocation
Interventional model
Masking
300 participants in 1 patient group
Loading...
Central trial contact
Jozef Murar; Elizabeth Shaji
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal